Barge Joseph La Sells 3,000 Shares of Spark Therapeutics Inc. (ONCE) Stock
Spark Therapeutics Inc. (NASDAQ:ONCE) insider Barge Joseph La sold 3,000 shares of the stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $60.14, for a total transaction of $180,420.00. Following the sale, the insider now owns 8,325 shares of the company’s stock, valued at approximately $500,665.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) opened at 60.49 on Friday. The firm’s market capitalization is $1.85 billion. The company has a 50 day moving average of $59.35 and a 200-day moving average of $49.53. Spark Therapeutics Inc. has a 12 month low of $21.20 and a 12 month high of $65.99.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by $0.07. The company earned $1.29 million during the quarter, compared to analyst estimates of $1.17 million. Spark Therapeutics had a negative net margin of 366.76% and a negative return on equity of 26.96%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period last year, the firm earned ($0.60) EPS. Analysts predict that Spark Therapeutics Inc. will post ($3.96) EPS for the current year.
ONCE has been the topic of a number of research analyst reports. Jefferies Group reissued a “hold” rating on shares of Spark Therapeutics in a report on Friday, August 5th. Zacks Investment Research lowered shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 16th. Chardan Capital set a $35.00 price objective on shares of Spark Therapeutics and gave the stock a “hold” rating in a report on Thursday, July 21st. Cantor Fitzgerald reissued a “buy” rating on shares of Spark Therapeutics in a report on Monday, June 13th. Finally, SunTrust Banks Inc. increased their price objective on shares of Spark Therapeutics from $64.00 to $72.00 and gave the stock a “buy” rating in a report on Tuesday, June 21st. Two research analysts have rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $59.50.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Teacher Retirement System of Texas increased its position in Spark Therapeutics by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 2,432 shares of the company’s stock worth $124,000 after buying an additional 299 shares during the period. ProShare Advisors LLC increased its position in shares of Spark Therapeutics by 6.5% in the second quarter. ProShare Advisors LLC now owns 22,493 shares of the company’s stock valued at $1,150,000 after buying an additional 1,372 shares during the last quarter. Legal & General Group Plc increased its position in shares of Spark Therapeutics by 105.6% in the second quarter. Legal & General Group Plc now owns 2,714 shares of the company’s stock valued at $138,000 after buying an additional 1,394 shares during the last quarter. Tocqueville Asset Management L.P. increased its position in shares of Spark Therapeutics by 4.1% in the second quarter. Tocqueville Asset Management L.P. now owns 50,650 shares of the company’s stock valued at $2,590,000 after buying an additional 2,000 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Spark Therapeutics during the second quarter valued at approximately $124,000. 78.79% of the stock is owned by institutional investors and hedge funds.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.